Also, I'm very interested in AP113's response in treatment naive pts as compared to those who have failed crizotinb. This could end up being a real point of differentiation vis-a-vis LDK378.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.